SK Minerals & Additives (544584)

Score breakdown: P/E: 3/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 32.29% reflects strong capital efficiency and possible pricing power in a niche specialty chemicals business.
• P/E of 11.62 with PEG of 0.36 suggests the market is pricing in far less growth than the recent 55.65% profit growth.
• Piotroski F-Score of 7/9 indicates solid financial health across profitability, leverage, and efficiency measures.
• Latest quarter sales of ₹110 crore and net profit of ₹7 crore confirm the business is generating real earnings.
• Profit growth far exceeding sales growth points to operating leverage and margin expansion.

Concerns

• Dividend yield is 0.00%, so returns depend entirely on capital appreciation and reinvestment success.
• Sales growth of only 8.83% is far below profit growth of 55.65%, raising questions about margin sustainability.
• Book value, debt/equity, promoter holding, and 52-week range are unavailable, limiting a complete Graham-style safety check.
• Market cap of ₹156 crore is small, which can bring volatility and lower liquidity.

AI Analysis

At ₹127.70, SK Minerals has a market cap of ₹156 crore and trades at 11.62 times earnings. That is not a demanding price for a specialty chemicals business earning a ROCE of 32.29%. Charlie and I like businesses that can deploy capital at high returns; this one seems to do that. The Piotroski score of 7/9 suggests the financials are in reasonable shape, and a PEG of 0.36 implies the market is paying little for the growth on offer. Profit growth of 55.65% is far ahead of revenue growth of 8.83%, so the leverage is coming from margins and operating efficiency rather than top-line momentum. That can be good—it shows cost discipline—but it also means I must watch whether margins can hold. The latest quarter shows sales of ₹110 crore and net profit of ₹7 crore, roughly a 6% margin, so the profit story is real but not without execution risk. There is no dividend, so this is a reinvestment story, not an income story. As Graham would say, price is what you pay, value is what you get. At 11.62 times earnings with strong return on capital, there appears to be a margin of safety if growth continues. But I cannot ignore what I do not know: book value, debt/equity, promoter holding, and the 52-week range are absent. In small-cap specialty chemicals, governance and balance-sheet strength matter immensely. I would want those figures before taking a large position. Still, on the numbers available, this looks like a fast-growing small business with a reasonable valuation and high returns on capital, albeit one demanding monitoring.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer